Nuwellis, Inc. has expanded its collaboration with a major South Carolina healthcare system to install new Aquadex SmartFlow® devices at one of its children’s hospitals and upgrade existing devices at two other locations. These devices help manage fluid overload in pediatric patients by providing precise ultrafiltration therapy, potentially reducing rehospitalizations linked to heart failure. Nuwellis is also seeking FDA approval to extend the device's use to smaller pediatric patients weighing 5 kg and above, with a submission expected by the end of 2026. This expansion highlights Nuwellis’ growing leadership in pediatric cardiorenal care technology.
Nuwellis, a medical technology company focused on cardiorenal conditions, has closed a public offering raising approximately $6 million. The offering included common stock, pre-funded warrants, and Series C and D warrants, with proceeds aimed at supp...
Nuwellis, Inc., a medical technology company focused on cardiorenal conditions, has closed a public offering raising approximately $6 million. The offering included common stock and warrants, priced around $0.30 per share and warrant. Proceeds will s...
